Randomized, Double-blind, Placebo Controlled Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Doses (Intravenous Bolus) and Constant Intravenous Infusion Over 7 Days of GSK3335065 in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 06 Jul 2018
At a glance
- Drugs GSK-3335065 (Primary)
- Indications Pancreatitis
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 05 Jun 2018 Planned End Date changed from 11 Jul 2018 to 18 Jul 2019.
- 05 Jun 2018 Planned primary completion date changed from 11 Jul 2018 to 18 Jul 2019.